The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) common stock between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). Chemours investors have until December 7, 2026 to file a lead plaintiff motion.
IF YOU SUFFERED A LOSS ON YOU’RE THE CHEMOURS COMPANY (CC) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.
You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com.
What Happened?
On August 4, 2026, Chemours announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.”
On this news, Chemours shares fell $3.34, or 18.63%, to close at $14.59 per share on August 5, 2026, thereby injuring investors.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (i) Defendants had materially overstated aftermarket demand for their Opteon products; (ii) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (iii) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Contact Us To Participate or Learn More:
If you purchased Chemours common stock, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at:
Law Offices of Frank R. Cruz
2121 Avenue of the Stars, Suite 800
Century City, CA 90067
Telephone: 310-914-5007
Email: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261009148034/en/
Media gallery
